Business
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n\n\n\n WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Company reports record revenue of\n \n $1.0 million\n \n , an increase of approximately 600% over the second quarter of 2023\n \n\n\n\n Signed strategic partnership with leading pharmaceutical manufacturer, Laurus Labs, to develop biobased processes for seven high value APIs with large, existing markets\n \n\n\n\n Company now anticipates revenue of over\n \n $4 million\n \n in 2024 on existing programs\n \n\n\n\n\n SUNNYVALE, Calif.\n \n\n ,\n \n\n Aug. 12, 2024\n \n\n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended\n \n June 30, 2024\n \n , reporting significantly higher revenue and reduced costs.\n \n\n\n\n\n\n\n\n\n \"The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs (\"Laurus\") strategic partnership that includes seven high value APIs,\" said Dr.\n \n Chris Savile\n \n , Willow's President & CEO. \"In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs\", added Dr. Savile.\n \n\n\n Second quarter and recent corporate highlights\n \n\n\n\n On\n \n May 30, 2024\n \n , Willow announced a multi-product development and licensing partnership with Laurus, a leading research-driven pharmaceutical and biotechnology company with a\n \n $3.9 billion\n \n market cap that serves global pharmaceutical companies and offers CDMO services. Under the terms of the collaboration which includes seven high-value advanced intermediates and ...